Clinical Trial Details

Short Title
Official Title
Study for Therapy of Metastatic Malignant Melanoma

A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma

Participants in this research study have been diagnosed with Stage IV malignant melanoma (melanoma that has spread to other parts of the body) which cannot be removed with surgery. The purpose of this study is to find out what effects (good and bad) the combination of the study drugs (Carboplatin, paclitaxel, bevacizumab and everolimus) has on the participant and the melanoma. Approximately 7 people will take part in this study conducted by Investigators at the University of Iowa. Participation in the study will continue until cancer becomes worse or participant or Doctor decide to end the treatment.

Start Date
October 25, 2012
End Date
March 1, 2015
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Mohammed Milhem, MD
Contact Info

Clarine Halvorsen 319-356-3944

cancer ; IRB#201208719 ; melanoma ; Milhem ; Phase 2 ; Phase II ;

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks